Christopher Fox, Phd
Chief Operations Officer
Since joining IDRI in 2007, Chris has played an integral role in developing, characterizing, and manufacturing cGMP vaccine adjuvant formulations for a variety of infectious diseases, including leishmaniasis, malaria, tuberculosis, pandemic influenza, and amebiasis, resulting >40 publications. He currently serves as principal investigator on a $11.9M contract from the National Institutes of Health (NIH) to develop a thermostable tuberculosis vaccine suitable for distribution in developing countries, involving formulation development, cGMP manufacturing, and clinical testing.
From 2010-2014, he led a $1.4M BARDA-funded effort to transfer adjuvant manufacturing technology to the Cantacuzino Institute in Bucharest, Romania. He has also participated in technology transfer projects in Brazil and India, where a vaccine formulation center has been constructed to manufacture IDRI-developed adjuvant formulations for clinical trials to evaluate malaria, leishmania, and tuberculosis vaccines.